Memory Pharmaceuticals Development Pipeline
| Drug Candidate | Indication | Status | Partner | |
|---|---|---|---|---|
| Nicotinic alpha-7 Agonists | MEM 3454 | Alzheimer's | Phase 2a completed | Roche |
| MEM 3454 | Schizophrenia (CIAS) | Phase 2a | ||
| R4996 / MEM 63908 | Alzheimer's | Phase 1 | ||
| Advanced Leads | CNS | Preclinical | ||
| PDE4 Inhibitors | MEM 1414 | Alzheimer's | Phase 1 | Memory-Owned |
| MEM 1917 | Alzheimer's | Preclinical | ||
| Advanced Leads | CNS | Preclinical | ||
| PDE10 Inhibitors | Advanced Leads | Neurological and Psychiatric Disorders | Preclinical | Amgen |
| 5HT6 Antagonists | Advanced Leads |
Alzheimer's Schizophrenia Attention Deficit Disorder Obesity | Preclinical | Memory-Owned |
| L-Type Calcium Channel Modulator | MEM 1003 |
Alzheimer's MCI Vascular Dementia |
Phase 2a completed | Memory-Owned |